BRPI0516247A - métodos de tratamento hormonal, utilizando regimes de ciclo prolongado de dose crescente - Google Patents

métodos de tratamento hormonal, utilizando regimes de ciclo prolongado de dose crescente

Info

Publication number
BRPI0516247A
BRPI0516247A BRPI0516247-5A BRPI0516247A BRPI0516247A BR PI0516247 A BRPI0516247 A BR PI0516247A BR PI0516247 A BRPI0516247 A BR PI0516247A BR PI0516247 A BRPI0516247 A BR PI0516247A
Authority
BR
Brazil
Prior art keywords
treatment methods
hormonal treatment
increasing dose
period
prolonged cycle
Prior art date
Application number
BRPI0516247-5A
Other languages
English (en)
Inventor
Charles E Diliberti
Kathleen Z Reape
Lance J Bronnenkant
Original Assignee
Duramed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duramed Pharmaceuticals Inc filed Critical Duramed Pharmaceuticals Inc
Publication of BRPI0516247A publication Critical patent/BRPI0516247A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODOS DE TRATAMENTO HORMONAL, UTILIZANDO REGIMES DE CICLO PROLONGADO DE DOSE CRESCENTE. A presente invenção proporciona regiões de ciclo prolongado de dose crescente, em que se administra a uma mulher, um estrogênio e uma progestina durante um período maior que 30 ou 31 dias consecutivos, opcionalmente seguido por um período isento de hormónio, ou por um período de administração de estrogênio. Os regimes revelados podem ser administrados a uma mulher com a finalidade de proporcionar benefícios contraceptivos, bem como, não contraceptivos.
BRPI0516247-5A 2004-10-07 2005-10-07 métodos de tratamento hormonal, utilizando regimes de ciclo prolongado de dose crescente BRPI0516247A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61642404P 2004-10-07 2004-10-07
US68456805P 2005-05-26 2005-05-26
PCT/US2005/035997 WO2006042021A2 (en) 2004-10-07 2005-10-07 Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

Publications (1)

Publication Number Publication Date
BRPI0516247A true BRPI0516247A (pt) 2008-08-26

Family

ID=36001184

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516247-5A BRPI0516247A (pt) 2004-10-07 2005-10-07 métodos de tratamento hormonal, utilizando regimes de ciclo prolongado de dose crescente

Country Status (11)

Country Link
US (1) US20060135496A1 (pt)
EP (3) EP1814556A2 (pt)
JP (1) JP2008515909A (pt)
AR (1) AR051931A1 (pt)
AU (1) AU2005294269B2 (pt)
BR (1) BRPI0516247A (pt)
CA (1) CA2582530A1 (pt)
IL (1) IL182287A0 (pt)
MX (1) MX2007004120A (pt)
TW (1) TW200626161A (pt)
WO (1) WO2006042021A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032756A1 (en) * 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
MXPA04005445A (es) * 2001-12-05 2005-03-23 Barr Lab Inc Anticonceptivos orales para prevenir el embarazo y disminuir la sintomatologia premenstrual.
WO2003094937A1 (en) * 2002-05-09 2003-11-20 Medigenes A pharmaceutical composition for treatment of wounds containing blood plasma or serum
NZ585546A (en) * 2003-07-16 2011-10-28 Teva Womens Health Inc Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
KR20090029237A (ko) 2006-06-02 2009-03-20 피어 트리 파머슈티칼스 인코포레이티드 위축성 질염을 치료하는 방법
EP1930010A1 (de) * 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
EP2343963B1 (en) 2008-10-08 2019-04-10 Agile Therapeutics, Inc. Transdermal delivery
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
CA2740004A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
WO2010111488A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530839A (en) * 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) * 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US5010070A (en) * 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
US4962098A (en) * 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
IE61236B1 (en) 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
AU3888597A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) * 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US7297688B2 (en) * 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
MXPA04005445A (es) * 2001-12-05 2005-03-23 Barr Lab Inc Anticonceptivos orales para prevenir el embarazo y disminuir la sintomatologia premenstrual.
US20030219471A1 (en) * 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
BR0309032A (pt) * 2002-04-03 2005-02-01 Barr Lab Inc Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores
JP2006525358A (ja) * 2003-05-02 2006-11-09 ドゥラメド ファーマシューティカルズ， インコーポレイテッド 長期周期避妊養生法を利用するホルモン治療の方法
NZ585546A (en) * 2003-07-16 2011-10-28 Teva Womens Health Inc Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
JP2007507534A (ja) * 2003-10-01 2007-03-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 持続的三相避妊方法
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens

Also Published As

Publication number Publication date
WO2006042021A3 (en) 2006-06-08
WO2006042021A2 (en) 2006-04-20
EP2392333A1 (en) 2011-12-07
CA2582530A1 (en) 2006-04-20
EP1814556A2 (en) 2007-08-08
MX2007004120A (es) 2007-06-15
JP2008515909A (ja) 2008-05-15
AU2005294269A1 (en) 2006-04-20
US20060135496A1 (en) 2006-06-22
AR051931A1 (es) 2007-02-21
AU2005294269B2 (en) 2011-07-28
TW200626161A (en) 2006-08-01
EP2392332A1 (en) 2011-12-07
WO2006042021B1 (en) 2006-08-03
IL182287A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
BRPI0412493A (pt) métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
AR047529A1 (es) Compuestos de quinolina sustituidos
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
NO20044699L (no) Vaginalpleiesammensetning
DE60115842D1 (de) Ventilanordnung
BR0313694A (pt) Derivados de pirazol, composição medicinal contendo os mesmos, seu uso medicinal e intermediários para sua produção
BRPI0507984A (pt) composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamìfero, para melhorar a resistência de insulina em um mamìfero e para prevenir ou tratar doenças circulatórias em um mamìfero, e, uso do composto
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
CY1111433T1 (el) Φαρμακευτικο τυποποιημενο παρασκευασμα δεσιταβινης
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
SE0001899D0 (sv) New compounds
EA201390332A1 (ru) Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
NO20080824L (no) Oral prevensjon med trimegeston
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
SE0401342D0 (sv) Therapeutic compounds
BR0313526A (pt) Medicamento inalativos que contêm um agente anticolinérigo, em combinação com corticoesteróides e betamiméticos
UY28945A1 (es) Derivados de pirrolopiridina
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
BRPI0410968A (pt) combinação unitária de fsh e hcg
MXPA02012730A (es) Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide.
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
PE20031047A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
MX2022009081A (es) Absorcion celular.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TEVA WOMEN'S HEALTH, INC. (US)

Free format text: NOME ALTERADO DE: DURAMED PHARMACEUTICALS, INC.

B25G Requested change of headquarter approved

Owner name: TEVA WOMEN'S HEALTH, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 018110020180/SP DE 30/05/2011.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.